Abaloparatide Powder Cas No.247062-33-5
Source: Synthetic
Specification: ≥98%
CAS No.: 247062-33-5
Molecular Formula: C₁₇₄H₃₀₀N₅₆O₄₉
Molecular Weight: ≈ 3960 Da
Testing Method: HPLC
Active Ingredient: Abaloparatide
Product CharacteristicsProduct Characteristics: White or off-white lyophilized powder
Packaging: 1–100 g/vial; 1 kg/aluminum foil bag; 25 kg/drum
Storage Condition: Store at -20 °C ± 5 °C, protected from light and moisture
Shelf Life: 24 months
Declaration of Use: This product is intended for industrial use or scientific research only.
Products Description
We specialise in the production and supply of high-purity abapentanapeptide active pharmaceutical ingredient (API). Leveraging advanced total synthetic technology and stringent quality control systems, our product exhibits identical chemical and physical properties to the reference standard. Our scalable manufacturing capacity can meet your requirements across all phases, from clinical research to commercial production.
We are committed to providing clients with reliable products meeting stringent pharmaceutical standards and professional supply chain support, serving as your trusted strategic partner.
Pharmacological Action
Abaloparatide is a synthetic polypeptide drug classified as a skeletal anabolic agent. Its core pharmacological action is to significantly stimulate new bone formation. While it moderately increases bone resorption, the overall effect is a substantial increase in bone mass and improvement of bone microarchitecture.
Mechanism of Action
As an analog of human parathyroid hormone-related protein (PTHrP), Abaloparatide is a highly selective, high-affinity agonist of the parathyroid hormone type 1 receptor (PTH1R). Upon binding to PTH1R, it preferentially and sustainedly activates the Gs/cAMP/PKA signaling pathway (the canonical pathway). This unique activation pattern enables it to more potently stimulate osteoblast proliferation and differentiation, demonstrating superior efficacy in promoting new bone formation compared to traditional therapies, while having a weaker effect on osteoclast-mediated bone resorption. This results in a wider anabolic window.
Product Efficacy
| Significant increase in Bone Mineral Density (BMD) | Substantial gains in BMD are observed at key sites, including the lumbar spine and hip. |
| Effective reduction of fracture risk |
By enhancing bone strength and improving bone quality, it significantly reduces the risk of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis. |
Product Application
As a high-purity Active Pharmaceutical Ingredient (API), its main applications are:
| Pharmaceutical Manufacturing | Used in the production of final drug products (e.g., injectable solutions) indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture. |
| Research & Development | Utilized in the development of novel drug delivery systems (e.g., transdermal patches, oral formulations), generic drug research, and further investigation into the mechanisms of skeletal metabolic diseases. |
Hot Tags: abaloparatide powder cas no.247062-33-5, China abaloparatide powder cas no.247062-33-5 manufacturers, suppliers, factory, tranexamic powder
You Might Also Like
Send Inquiry